Bridgefront Capital’s Myriad Genetics MYGN Stock Holding History

Bridgefront Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,400	Closed	-$145K	–	762
2025 Q1	$145K	Buy	+16,400	New	+$197K	0.04%	558

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Bridgefront Capital's MYGN Position: Q2 2025 in Review

Bridgefront Capital sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 16,400 shares — an estimated $145K sold.

Bridgefront Capital first reported a position in MYGN in Q1 2025 and held it in 1 quarter. The position peaked at $145K in Q1 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

Bridgefront Capital reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
Bridgefront Capital sold 16,400 Myriad Genetics shares in Q2 2025, an estimated $145K.
Bridgefront Capital first reported a position in Myriad Genetics in Q1 2025 and held it in 1 quarter.
Bridgefront Capital's Myriad Genetics position peaked at $145K in Q1 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.